Biblio Discovery — Demo Discovery Service

27 results for "Colomba, Emeline"

Showing 1–20 · 5.93 seconds · RSS

  1. Journal Article Full text

    Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

    Lavaud, Pernelle; Dumont, Clément; Thibault, Constance et al.

    Ther Adv Med Oncol · 2020 · English · PubMed Central

    Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in…

  2. Journal Article Full text

    Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma

    Guida, Annalisa; Le Teuff, Gwénaël; Alves, Carolina et al.

    Oncotarget · 2020 · English · PubMed Central

    Majority of patients with clear-cell renal cell carcinoma (ccRCC) at first line (1L) treatment are classified in the intermediate-risk (IR) subgroup according to International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score. As these patients have different prognosis, the aim of…

  3. Journal Article Full text

    Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report

    Aldea, Mihaela; Belkhir, Rakiba; Colomba, Emeline et al.

    Front Immunol · 2022 · English · PubMed Central

    Radiotherapy can trigger immune-related out-of-field “abscopal” response. We report a patient with advanced NSCLC (non-small cell lung cancer) receiving long-term anti-PD1 (programmed cell death protein 1) who have developed out-of-field immune-related arthritis following pelvic irradiation.

  4. Journal Article Full text

    Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma

    Colomba, Emeline; Alves Costa Silva, Carolina; Le Teuff, Gwénaël et al.

    J Cachexia Sarcopenia Muscle · 2022 · English · PubMed Central

    BACKGROUND: Cabozantinib, a standard of care metastatic renal cell carcinoma (mRCC), may be associated with weight and muscle loss. These effects of new generation VEGFR tyrosine kinase inhibitor on muscle mass loss are poorly described. METHODS: All cabozantinib‐treated mRCC patients from January…

  5. Journal Article Full text

    The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma

    Rassy, Elie; Cerbone, Luigi; Auclin, Edouard et al.

    Oncologist · 2021 · English · PubMed Central

    INTRODUCTION: Cabozantinib is an oral tyrosine kinase inhibitor that is approved for the treatment of metastatic renal cell carcinoma (mRCC). Cabozantinib is a weak base that exhibits a pH‐dependent solubility profile in vitro which raises concerns about its bioavailability in patients treated with…

  6. Journal Article Full text

    Molecular profiling of endometrial cancer in Martinique reveals frequent CCNE1 amplification in poor prognosis tumors

    Labeau, Taina; Loger, Jean-Samuel; Jean-Laurent, Mehdi et al.

    Sci Rep · 2025 · English · PubMed Central

    PURPOSE: In Martinique, there is an unmet need in EC management. Although the incidence rate is similar to that in mainland France, the mortality rate is higher, potentially due to the over-incidence of high-grade tumors. Recently, we reported CCNE1 amplification in 70% of these tumors which have a…

  7. Journal Article Full text

    Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study

    Guillaume, Zoé; Colomba, Emeline; Thouvenin, Jonathan et al.

    Cancers (Basel) · 2022 · English · PubMed Central

    SIMPLE SUMMARY: Collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) are two rare cancers with a very poor prognosis. Currently, first-line treatment is a platinum-based doublet, but very few studies have evaluated the effectiveness of treatments for subsequent lines. Additionally…

  8. Journal Article Full text

    NCOG-19. BEVACIZUMAB IN REAL LIFE PATIENTS WITH RECURRENT GLIOBLASTOMA: BENEFIT OR FUTILITY?

    Smolenschi, Cristina; Colomba, Emeline; Rassy, Elie et al.

    Neuro Oncol · 2020 · English · PubMed Central

    Angiogenesis represents a hallmark of glioblastoma but most trials disappointed and failed to change the poor outcome of this disease. However, Bevacizumab (Bev) is widely used in clinical practice by expert oncologists due to experience or efficacy in real life.We retrospectively reviewed the use…

  9. Journal Article Full text

    Copy number signatures and CCNE1 amplification reveal the involvement of replication stress in high-grade endometrial tumors oncogenesis

    Marlin, Regine; Loger, Jean-Samuel; Joachim, Clarisse et al.

    Cell Oncol (Dordr) · 2024 · English · PubMed Central

    PURPOSE: Managing high-grade endometrial cancer in Martinique poses significant challenges. The diversity of copy number alterations in high-grade endometrial tumors, often associated with a TP53 mutation, is a key factor complicating treatment. Due to the high incidence of high-grade tumors with…

  10. Journal Article Full text

    Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma

    Parent, Pauline; Auclin, Edouard; Patrikidou, Anna et al.

    Cancers (Basel) · 2023 · English · PubMed Central

    SIMPLE SUMMARY: In this report, we studied the role of the LIPI score, a biological score based on 2 factors, derived neutrophils/(leukocytes minus neutrophils) ratio and lactate dehydrogenase, in population with unresectable urothelial cancer treated with immune checkpoint inhibitor (ICI). This…

  11. Journal Article Full text

    Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers

    Nebot-Bral, Laetitia; Hollebecque, Antoine; Yurchenko, Andrey A et al.

    J Immunother Cancer · 2022 · English · PubMed Central

    BACKGROUND: Clinical studies have highlighted the efficacy of anti-programmed death 1 (αPD-1) monoclonal antibodies in patients with DNA mismatch repair-deficient (MMRD) tumors. However, the responsiveness of MMRD cancers to αPD-1 therapy is highly heterogeneous, and the origins of this variability…

  12. Journal Article Full text

    A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1

    Agarwal, Neeraj; Castellano, Daniel; Alonso-Gordoa, Teresa et al.

    Clin Cancer Res · 2024 · English · PubMed Central

    PURPOSE: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors radically changed the treatment paradigm for breast cancer. Similar to estrogen receptor in breast cancer, androgen receptor signaling activates cyclin D–CDK4/6, driving proliferation and resistance to hormonal manipulation in prostate…

  13. Journal Article Full text

    Impact of COVID-19 on healthcare organisation and cancer outcomes

    Bardet, Aurelie; Fraslin, Alderic M.; Marghadi, Jamila et al.

    Eur J Cancer · 2021 · English · PubMed Central

    BACKGROUND: Changes in the management of patients with cancer and delays in treatment delivery during the COVID-19 pandemic may impact the use of hospital resources and cancer mortality. PATIENTS AND METHODS: Patient flows, patient pathways and use of hospital resources during the pandemic were…

  14. Journal Article Full text

    Prevalence and clinical significance of the rare HOXB13 X285K variant in a French Caribbean prostate cancer cohort

    Rose-Dite-Modestine, Johan; Vallard, Alexis; Loger, Jean-Samuel et al.

    BMC Cancer · 2025 · English · PubMed Central

    BACKGROUND: The HOXB13 gene has been associated with hereditary prostate cancer (PCa), with rare germline variants linked to early-onset and aggressive forms of the disease. While the G84E variant has been well-characterized in Caucasian populations, the clinical relevance of the X285K…

  15. Journal Article Full text

    Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice

    Lorusso, Domenica; Colombo, Nicoletta; Herraez, Antonio Casado et al.

    Eur J Cancer · 2023 · English · PubMed Central

    PURPOSE: Lenvatinib and pembrolizumab (LEN+PEMBRO) demonstrated clinically meaningful and statistically significant improvements in efficacy versus treatment of physician’s choice (TPC) in patients with advanced endometrial cancer (aEC) in the phase 3 Study 309/KEYNOTE-775. Health-related…

  16. Journal Article Full text

    Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade

    Ferrere, Gladys; Tidjani Alou, Maryam; Liu, Peng et al.

    JCI Insight · 2021 · English · PubMed Central

    Limited experimental evidence bridges nutrition and cancer immunosurveillance. Here, we show that ketogenic diet (KD) — or its principal ketone body, 3-hydroxybutyrate (3HB), most specifically in intermittent scheduling — induced T cell–dependent tumor growth retardation of aggressive tumor models…

  17. Journal Article Full text

    Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

    Lièvre, Astrid; Turpin, Anthony; Ray-Coquard, Isabelle et al.

    Eur J Cancer · 2020 · English · PubMed Central

    BACKGROUND: Cancer patients are thought to have an increased risk of developing severe Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, predictive factors for COVID-19 severity and mortality in cancer patients were investigated. PATIENTS AND METHODS: In…

  18. Journal Article Full text

    Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

    Makker, Vicky; Colombo, Nicoletta; Herráez, Antonio Casado et al.

    N Engl J Med · 2022 · English · PubMed Central

    BACKGROUND: Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear. METHODS: In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previously received at least one platinum-based…

  19. Journal Article Full text

    EpCAM(high) and EpCAM(low) circulating tumor cells in metastatic prostate and breast cancer patients

    de Wit, Sanne; Manicone, Mariangela; Rossi, Elisabetta et al.

    Oncotarget · 2018 · English · PubMed Central

    The presence of high expressing epithelial cell adhesion molecule (EpCAM(high)) circulating tumor cells (CTC) enumerated by CellSearch(®) in blood of cancer patients is strongly associated with poor prognosis. This raises the question about the presence and relation with clinical outcome of low…

  20. Journal Article Full text

    Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775

    Makker, Vicky; Colombo, Nicoletta; Casado, Antonio et al.

    J Immunother Cancer · 2026 · English · PubMed Central

    BACKGROUND: In Study 309/KEYNOTE-775 (NCT03517449), lenvatinib+pembrolizumab versus chemotherapy significantly improved progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced endometrial cancer (EC). We report 5-year follow-up results. METHODS…